Login to Your Account

FDA Gives its Nod to Procysbi; Raptor Ascends

By Marie Powers
Staff Writer

Tuesday, April 30, 2013
The FDA put some lift under the wings of Raptor Pharmaceutical Corp., approving the orphan drug Procysbi (RP103, cysteamine bitartrate delayed-release) on its PDUFA date in the initial indication of nephropathic cystinosis (NC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription